A groundbreaking cholesterol-lowering medication is reshaping the landscape of heart disease prevention. New research indicates that evolocumab, a drug typically administered to individuals with existing cardiovascular conditions, can significantly lower the risk of initial heart attacks and strokes in high-risk diabetic patients. This benefit was observed even before any signs of artery-clogging plaque were detected, suggesting a proactive and transformative approach to preventing serious cardiac events.
Potent Cholesterol Drug Dramatically Reduces Heart Attack Risk by 31%
By Rupert Blackwood
Investigative journalist based in Sheffield, focusing on technology's impact on society. Rupert specializes in cybercrime's effect on communities, from online fraud targeting elderly residents to cryptocurrency scams. His reporting examines social media manipulation, digital surveillance, and how criminal networks operate in cyberspace. With expertise in computer systems, he connects technical complexity with real-world consequences for ordinary people